Browse drugs

…) for preventing exacerbations. Our findings indicate that LABA+LAMA is superior to LABA+ICS in preventing moderate to severe exacer…

…ating therapy with LABA-ICS inhalers may be more effective than LABA-LAMA inhalers among patients with multiple exacerbations, particular…

…med a post hoc analysis of the 52-week, double-blind, Effect of Indacaterol Glycopyrronium versus Fluticasone Salmeterol on COPD Exacerbations trial that …

…–113.63; p<0.001), ICS (OR=32.50, 95% CI 6.70–157.44; p<0.001), montelukast (OR=16.60, 95% CI 6.35–43.38; p<0.001), and LABA (OR=5.65, 95% …

…talisations. This trial will bridge the gap for the efficacy of budesonide/formoterol in children <12 years of age and address the economic arguments…

…A long-acting muscarinic antagonist (LAMA) may be added to medium-/high-dose inhaled corticosteroid (ICS)…

…acting β2-agonists (LABAs), long-acting muscarinic antagonists (LAMAs) and triple therapy (ICS/LABA/LAMA), on exacerbation rates and …

…meter (MMAD) were compared across all active components.Results BDP/FF/GB pMDI demonstrated substantially greater eFPF vs either BUD/FF/GB pMD…

…rmacy was associated with gender and disease severity. LABA and ICS were the most frequently prescribed medications. As new therapi…

…mainly treated with bronchodilators (long-acting beta-agonists (LABA) and/or long-acting muscarinic antagonists (LAMA)) to reduce sy…